LIXT News & Events

Lixte Biotechnology announced the presentation of preliminary results for a clinical trial testing the combination of Lixte's proprietary compound LB100 in combination with Dostarlimab at the 2026 Conference of the Society of Gynecological Cancer, April 10-13, in San Juan, Puerto Rico. At a median follow-up length of 12 months, median OS has not been reached. However, OS probability was 0.84 at 6 months and 0.69 at 12 months. The Disease Control Rate was 40%. Specifically, prior investigation reported markedly prolonged overall survival with ICB in patients with PPP2R1A-mutant OCCC. This suggested that reducing PP2A pharmacologically with LB-100 may enhance the anti-tumor effect of the PD-1 blocking monoclonal antibody, dostarlimab-gxly, in patients with Ovarian Clear Cell Carcinoma lacking the genetic reduction in PP2A.

LIXTE Biotechnology has appointed Sidney Braun as CEO of the Company's Liora Technologies Europe Ltd. subsidiary. A veteran of the healthcare industry, Braun brings to Liora more than two decades of operational and strategic advisory experience at companies in North America, Europe and Israel. He was instrumental in the creation of Liora and facilitated LIXTE's acquisition of Liora's assets in November 2025 from Orbit Capital, Inc.

LIXTE Biotechnology engaged IBN to assist with its corporate communications strategy. As part of the client-partner relationship, IBN will leverage its investor-focused distribution network, which includes over 5,000 key syndication outlets, various newsletters, social media channels, and wire services via InvestorWire, along with blogs and other outreach tools, to generate greater awareness for LIXTE Biotechnology.

LIXTE Biotechnology announced it is expanding its collaboration with The University of Texas MD Anderson Cancer Center and pharmaceutical manufacturer GSK on an ongoing clinical trial with LIXTE's proprietary compound, LB-100, to treat ovarian clear cell cancer. The trial, which combines LB-100 with GSK's Dostarlimab to enhance the effectiveness of immunotherapy, was initiated in January 2024. A second trial site was added earlier this year at the Robert H. Lurie Comprehensive Cancer Center of Northwestern University. MD Anderson and Northwestern Medical Center plan to double the number of enrollments in the trial to 42 patients, after successfully attaining its initial target of 21 patients earlier this year. The Company also announced that it expects data to be presented from the trial on the initial 21 patients in the first half of 2026.